VEGFA and neoplasm: Clinically-approved drugs including bevacizumab (Avastin®; Genentech) and sunitinib (Sutent<; Sugen) in addition to counterparts in clinical trials, including VEGF-TrapR1R2 (Aflibercept; Regeneron Inc.)and vendatanib (Caprelsa; AstraZeneca), illustrate the major emphasis placed on preventing tumor angiogenesis [24–27].